A rapidly progressing Pancoast syndrome due to pulmonary mucormycosis: a case report

Meghana Bansal1*, Sara R Martin2, Stacy A Rudnicki3, Kim M Hiatt4 and Eduardo Mireles-Cabodevila2

Abstract

Introduction: Pancoast syndrome is characterized by Horner syndrome, shoulder pain radiating down the arm, compression of the brachial blood vessels, and, in long-standing cases, atrophy of the arm and hand muscles. It is most commonly associated with lung carcinoma but rarely is seen with certain infections.

Case presentation: We present the case of a 51-year-old Caucasian man who had acute myeloid leukemia and who developed a rapidly fulminating pneumonia along with signs and symptoms of acute brachial plexopathy and left Horner syndrome. Also, a purpuric plaque developed over his left chest wall and progressed to skin necrosis. The skin biopsy and bronchoalveolar lavage showed a Rhizopus species, leading to a diagnosis of mucormycosis. This is a rare case of pneumonia due to mucormycosis associated with acute Pancoast syndrome.

Conclusions: According to our review of the literature, only a few infectious agents have been reported to be associated with Pancoast syndrome. We found only three case reports of mucormycosis associated with acute Pancoast syndrome. Clinicians should consider mucormycosis in their differential diagnosis in a patient with pulmonary lesions and chest wall invasion with or without neurological symptoms, especially in the setting of neutropenia or other immunosuppressed conditions. It is important to recognize this condition early in order to target therapy and interventions.

Introduction

Pancoast syndrome is most commonly associated with a primary lung carcinoma and rarely with metastatic malignancies and certain infections, including mucormycosis. It is characterized by Horner syndrome, shoulder pain radiating down the arm, compression of the brachial blood vessels, and, in long-standing cases, atrophy of the arm and hand muscles. Pulmonary mucormycosis usually occurs in the setting of hematological malignancies. The typical presentation is a patient with neutropenic fever, pulmonary infiltrates, and a clinical course that worsens despite antibiotics. We present a case of pulmonary mucormycosis associated with postchemotherapy neutropenia in a patient with acute myeloid leukemia. His course was fulminating, leading to chest wall invasion, brachial plexopathy, and Horner syndrome.

Case presentation

A 51-year-old Caucasian man was hospitalized for the management of a relapse of acute myeloid leukemia. He had hyperleukocytosis and complained of mild shortness of breath and generalized weakness. He denied cough, fevers or chills, hemoptysis, or orthopnea. He had smoked 39 pack years. His significant medical history began six months prior to admission, when his condition was diagnosed as acute myelomonocytic leukemia. He had been treated with cytarabine and daunorubicin followed by high-dose cytarabine. Shortly after admission, he required urgent leukopheresis because of worsening hyperleukocytosis and acute respiratory failure. He recovered and had further chemotherapy with clofarabine and cytarabine.

Eighteen days after admission, he was neutropenic and febrile. He developed left axillary burning pain, which evolved in a matter of hours to numbness of his arm. Soon afterward, weakness started in his hand and later moved proximally up his arm. At that time, he had a temperature of 38°C, a respiratory rate of 20 breaths per minute, a heart rate of 133 beats per minute, blood pressure of 117/77 mm Hg, and an oxygen saturation of 94% on 50% venturi mask. He was dyspneic and a chest examination...
revealed signs of lung consolidation in the left upper and left lower lobes. A chest radiograph (Figure 1) revealed elevation of the left hemidiaphragm, alveolar and interstitial opacities of the left upper lobe and lower lobe with air bronchograms, and blunting of the costophrenic angle. He was started on broad-spectrum antibiotics and voriconazole prophylaxis.

A physical examination revealed edema of the skin over the anterior left chest wall but no erythema, scaling, or discrete skin lesions. In a matter of hours, the numbness spread from a T1 distribution to a C8 distribution. The following day, his left arm was plegic with the exception of trace movement of the deltoid muscle. He also developed a left Horner syndrome. Further swelling developed in his left arm and anterosuperior chest with fullness in the supraclavicular fossa. Doppler ultrasound showed occlusion of his left distal subclavian, axillary, and brachial arteries and deep vein thrombosis of his left internal jugular, subclavian, and axillary veins. Heparin was started for his thrombosis, but soon after he had mild hemoptysis. A chest computed tomography scan (Figure 2) showed extensive edematous changes of the left chest wall and axilla along with left pleural effusion and pulmonary parenchymal consolidation. A bronchoscopy that revealed a blood clot in the left upper lobe bronchus without endobronchial lesions was performed.

Six days after the onset of numbness, a palpable purpuric plaque developed over his left chest and progressed to a 2 cm black eschar. A punch biopsy of the plaque was performed. With failure to respond with broad spectrum antibiotics (which included vancomycin, imipenem, voriconazole and acyclovir), liposomal amphotericin B 5 mg/kg per day was added empirically to his regimen. A histological evaluation of skin biopsy showed abundant angiocentric and angioinvasive ribbon-like hyphae with irregular nonparallel contours, occasional right-angle branching, and rare septae (Figures 3 and 4). Cultures from both skin and bronchoalveolar lavage confirmed a diagnosis of mucormycosis by a *Rhizopus* species. Twenty-four hours later, he developed respiratory distress, shock, and multiorgan failure resulting in death. An autopsy was declined by his next of kin.
Discussion

Mucormycosis is an uncommon opportunistic infection, but its incidence is increasing as the number of patients with diabetes, organ transplants, or immunosuppressed conditions continues to rise [1]. Hematological malignancies are more frequently associated with mucormycosis than solid tumors are [1]. In patients with hematological malignancies, mucormycosis affects the lungs most frequently (58% to 81%) [2].

Pulmonary mucormycosis occurs with inhalation of spores into the bronchioles and alveoli, usually resulting in a rapidly progressive pneumonia or endobronchial disease. Symptoms are typically nonspecific and may include fever, dyspnea, cough, and chest pain [2,3]. The infection can spread to contiguous organs or disseminate hematogenously. Of particular interest to our case is the overwhelming speed with which the process extended from the lung parenchyma to the surrounding structures (tissue, nerves, vessels, and skin). The progression of symptoms suggests that the lower brachial plexus trunk became ischemic initially and that the rest of the plexus followed as the lesion extended from the lung to the surrounding tissues. Mucor is known to locally invade nerves, most often in rhinocerebral disease. Common clinical findings include rhinitis, periorbital and facial swelling, mucosal necrosis, ophthalmoplegia, multiple cranial nerve palsies, facial pain, and headache [4]. Whereas stroke from rhinocerebral mucormycosis causing occlusion of the cavernous portion of the internal carotid is well documented [4], involvement of the brachial vascular and nervous plexus is a very unusual presentation. Three reports document mucormycosis presenting as a Pancoast syndrome [5-7]. Notably, two had diabetes (both survived) as their only risk factor and one had acute lymphoblastic leukemia (died).

Pancoast syndrome is characterized by Horner syndrome (ptosis, miosis, hemianhidrosis, and enophthalmos), shoulder pain radiating toward the axilla or ulcer aspect of the arm, compression of the brachial blood vessels, and atrophy of the arm and hand muscles. This syndrome is most commonly caused by a bronchogenic carcinoma in the superior sulcus of the lung with destructive lesions of the thoracic inlet and invasion of the brachial plexus and cervicothoracic sympathetic chain. Other causes include metastatic neoplasms and infections. In a recent review of 31 patients with infectious causes of Pancoast syndrome, five were immunocompromised (acute myelogenous leukemia, acute lymphoblastic leukemia, and postchemotherapy), and all had opportunistic organisms (Aspergillus spp., mucor, nocardia, and Pseudoallescheria boydii) [7]. In contrast, only one of the 26 immunocompetent patients had an opportunistic organism.

In immunocompromised patients, it can be challenging to distinguish pulmonary disease caused by mucormycosis from that caused by aspergillosis. The concomitant presence of sinusitis or a history of voriconazole prophylaxis may suggest mucormycosis [8,9]. Of note, our patient received voriconazole prophylaxis. The radiographic presentation of pulmonary mucormycosis can be diverse, and there are no pathognomonic radiographic features. In a review of imaging findings in 32 cases of mucormycosis, two thirds of the patients had consolidation as a main finding [10]. Other radiographic manifestations include cavitation, mass-like lesions, widened mediastinum, an “air crescent sign”, “halo sign”, pleural effusion, and fistula to the chest wall [10,11]. Chamilos and colleagues [8], in a retrospective chart review, found that multiple nodules (at least 10) and the presence of pleural effusion were more often found in mucormycosis than in aspergillosis.

Definitive diagnosis of mucormycosis often evades initial noninvasive techniques such as sputum and blood cultures. The organism may be recovered by bronchoscopy with bronchoalveolar lavage or transbronchial lung biopsy. However, because of the focal distribution of the disease, transthoracic computed tomography-guided needle biopsy or open lung biopsy may be required to make the diagnosis in pulmonary disease [1,12,13]. Histology is characterized by infarction and necrosis of tissue which results from an invasion of the vasculature by hyphae. The fungus can also be associated with neural, vascular, and cutaneous invasion, as in our patient. The fungus is usually recognized by broad, irregular, nonseptate, right-angled, branching hyphae and is demonstrated by hematoxylin and eosin and specialized fungal stains. In contrast, Aspergillus hyphae are narrow with septate branches at 45° angles.
As with other fungal diseases, mucorales rarely grow by culture.

Treatment of mucormycosis involves a combination of surgical debridement of involved tissues and antifungal therapy with varying degrees of success, as noted in the literature [1,14,15]. Amphotericin B is the first-line antifungal treatment; delays in instituting therapy may be associated with increased mortality. Elimination of predisposing factors for infection, such as hyperglycemia, metabolic acidosis, and neutropenia, is critical. Pulmonary mucormycosis carries a very high mortality rate (60% to 90%) [1,14].

Conclusions
It is important to consider the diagnosis of mucormycosis in a patient with pulmonary lesions and chest wall invasion with or without neurological symptoms, especially in the setting of neutropenia or other immunosuppressed conditions. Our patient had a rapid progression to multiorgan failure and refractory shock despite being treated with amphotericin B and died within two days of his diagnosis.

Consent
Written informed consent was obtained from the next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Author details
1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 2Division of Pulmonary and Critical Care Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 3Division of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 4Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Authors’ contributions
MB reviewed the literature and wrote a first draft of the manuscript, SRM reviewed the literature and edited the manuscript. SAR reviewed the literature and wrote the neurological features and discussion. KMH wrote the pathological discussion and edited the manuscript. EM-C reviewed the literature and corrected and finalized the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 18 April 2011 Accepted: 17 August 2011 Published: 17 August 2011

References
1. Lee FY, Mossad SB, Adal KA: Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999, 159:1301-1309.
2. Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, Covatta L, D’Antonio D, Girmina C, Martino P, Del Favero A: Mucormycosis in hematologic patients. Haematologica 2004, 89:207-214.
3. Bigby TD, Serota ML, Tierney LM Jr, Matthay MA: Clinical spectrum of pulmonary mucormycosis. Chest 1986, 89:635-639.
4. Warvar RE, Bullock JD: Rhino-orbital-cerebral mucormycosis: a review. Orbit 1998, 17:237-245.
5. Kotoulas C, Psathakis K, Tsigitzis K, Sampaziotis D, Kameisis L, Latoudis G: Pulmonary mucormycosis presenting as horner’s syndrome. Asian Cardiovasc Thorac Ann 2006, 14:86-87.
6. Levy H, Sacho H, Feldman C, Naude GE, Peskin J, Stead KJ, Kallenbach JM: Pulmonary mucormycosis presenting with horner’s syndrome. Report of a medical case. S Afr Med J 1986, 70:363-365.
7. White HD, White BA, Boethel C, Arroliga AC: Pancoast’s syndrome secondary to infectious etiologies: a not so uncommon occurrence. Ann J Med Sci 2011, 341:333-336.
8. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP: Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41:60-66.
9. Trifillo S, Singhal S, Williams S, Frankfort O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
10. McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF Jr: Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997, 168:1541-1548.
11. Murphy RA, Miller WT Jr: Pulmonary mucormycosis. Semin Roentgenol 1996, 31:83-87.
12. Kim K, Lee MH, Kim J, Lee KS, Kim SM, Jung MP, Han J, Sung KW, Kim WS, Jung CW, Yoon SS, Im YH, Kang WK, Park K, Park CH: Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Am J Hematol 2002, 71:75-79.
13. Eucker J, Sezer O, Graf B, Possinger K: Mucormycoses. Mycoses 2001, 44:253-260.
14. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE: Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994, 57:1044-1050.
15. Geissner B, Schilling A, Anagnostopoulos I, Siehl I, Thiel E: Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004, 45:1351-1360.

Cite this article as: Bansal et al.: A rapidly progressing Pancoast syndrome due to pulmonary mucormycosis: a case report. Journal of Medical Case Reports 2011, 5:388.